Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 3/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 4/20 | 0.40 |
| ▸ | CNR2 | P34972 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | APAF1 | O14727 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclopentanone SCHEMBL17048386 | 0.92 | PTGS1 (0.48) | PTGS1PTGS2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18589112 | 0.84 | PTGS1 (0.51) | PTGS1PTGS2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18589107 | 0.83 | PTGS1 (0.50) | PTGS1PTGS2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8167269 | 0.82 | ALOX15 (0.44) | PTGS1PTGS2NPC1RAB9AMAPT | |
| SCHEMBL18589111 | 0.81 | PTGS1 (0.48) | PTGS1PTGS2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17048402 | 0.77 | PTGS1 (0.51) | PTGS1PTGS2NPC1RAB9AMAPT | |
| SCHEMBL18589050 | 0.77 | PTGS1 (0.43) | PTGS1PTGS2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL26084688 | 0.76 | STS (0.41) | PTGS1PTGS2SMN1; SMN2MAPTLMNA | |
| SCHEMBL20220042 | 0.75 | GFER (0.42) | PTGS1PTGS2NPC1RAB9AMAPT | |
| SCHEMBL24746420 | 0.75 | SMN1; SMN2 (0.59) | NPC1RAB9ASMN1; SMN2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3110815-B1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | JIANGSU ASCENTAGE BIOMED DEV INC (CN) | 2020-02-19 | — | — | EP | disclosed |
| CN-106459033-B | Indoloquinolones as inhibitors of anaplastic lymphoma enzyme (A L K) | 江苏亚盛医药开发有限公司 | 2018-12-21 | — | — | CN | disclosed |
| US-9783539-B2 | Indoloquinolone compounds as anaplastic lymphoma kinase (ALK) inhibitors | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2017-10-10 | — | — | US | disclosed |
| US-9783539-B2 | Indoloquinolone compounds as anaplastic lymphoma kinase (ALK) inhibitors | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2017-10-10 | — | — | US | disclosed |
| US-9783539-B2 | Indoloquinolone compounds as anaplastic lymphoma kinase (ALK) inhibitors | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2017-10-10 | — | — | US | disclosed |
| US-20170066761-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2017-03-09 | — | — | US | disclosed |
| US-20170066761-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2017-03-09 | — | — | US | disclosed |
| US-20170066761-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2017-03-09 | — | — | US | disclosed |
| CN-106459033-A | Indoloquinolones as anaplastic lymphoma enzyme (ALK) inhibitors | 江苏亚盛医药开发有限公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-3110815-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | Jiangsu Ascentage Biomed Development Inc. (CN) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015127629-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015127629-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066761-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | ALK, BCL6, BCL6B | PTGS1 2288/4885PTGS2 2281/4885NPC1 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.